An eye on equity: faricimab-driven health equity improvements in diabetic macular oedema using a distributional cost-effectiveness analysis from a UK societal perspective.
Aurelie MeunierOyin OpeifaLouise LongworthOliver CoxChristian BührerIsabelle Durand-ZaleskiBrigid Ky NingRichard P GalePublished in: Eye (London, England) (2024)
Long-acting therapies with fewer injections, such as faricimab, may reduce costs, improve health outcomes and increase health equity. Extended economic evaluation frameworks capturing additional value elements, such as DCEA, enable a more comprehensive valuation of interventions, which is of relevance to decision-makers, healthcare professionals and patients.
Keyphrases
- public health
- healthcare
- end stage renal disease
- mental health
- ejection fraction
- chronic kidney disease
- global health
- newly diagnosed
- type diabetes
- prognostic factors
- optical coherence tomography
- physical activity
- health promotion
- decision making
- ultrasound guided
- climate change
- social media
- patient reported
- platelet rich plasma
- cataract surgery